Esketamine and Antidepressants for TRD: Meta-Analysis Insights

Esketamine Shows Rapid Improvement in TRD

Intranasal esketamine, when combined with an oral antidepressant, offers rapid improvement in treatment-resistant depression (TRD), according to a recent systematic review and meta-analysis. This study, published on July 3, 2026, analyzed data from six unique randomized controlled trials (RCTs) involving 1,836 participants, highlighting esketamine's potential to significantly reduce depressive symptoms within days of treatment initiation.

The analysis found that esketamine led to greater symptom reduction by day 28, with a mean difference (MD) of -2.99 on the Montgomery–Åsberg Depression Rating Scale (MADRS). Notably, rapid improvement was evident by day 2, with an MD of -3.25. This suggests that esketamine can provide quick relief for individuals with TRD, a condition notoriously difficult to treat.

Mechanism and Context of Esketamine's Efficacy

Esketamine, an enantiomer of ketamine, acts as an N-methyl-D-aspartate (NMDA) receptor antagonist. This mechanism is believed to facilitate synaptic plasticity and enhance neurogenesis, contributing to its antidepressant effects. The study's findings align with previous research indicating that NMDA receptor antagonists can produce rapid antidepressant effects.

The trials included in the meta-analysis compared intranasal esketamine plus an oral antidepressant to a placebo nasal spray with the same oral antidepressant. This combination therapy approach aims to leverage esketamine's rapid action while maintaining long-term stability with traditional antidepressants.

Policy and Research Implications

The findings have significant implications for clinicians and researchers exploring TRD treatment options. The rapid onset of esketamine's effects could be particularly beneficial for patients at high risk of suicide or severe functional impairment. However, the study underscores the necessity of supervised care due to the increased risk of adverse events.

Policy-wise, the results may influence guidelines and recommendations for TRD management, potentially integrating esketamine as a standard adjunctive treatment. This would require healthcare systems to adapt to the need for specialized supervision and monitoring of patients receiving esketamine.

Risks and Unknowns in Esketamine Use

While esketamine shows promise, the meta-analysis highlights several acute adverse events associated with its use. These include increased risks of dissociation and elevated blood pressure, necessitating careful benefit-risk assessment. The study reported a risk ratio (RR) of 7.33 for dissociation and 3.96 for increased blood pressure events, emphasizing the need for vigilant monitoring.

Additionally, the long-term effects of esketamine remain uncertain, particularly concerning its safety profile and potential for dependency. Further research is needed to explore these aspects and to optimize dosing regimens that balance efficacy with safety.

Future Directions and Considerations

Looking forward, the integration of esketamine into TRD treatment protocols will require ongoing evaluation of its long-term benefits and risks. Future studies should aim to refine patient selection criteria, identifying those who would benefit most from esketamine therapy while minimizing exposure to potential harms.

Moreover, the development of standardized protocols for administering esketamine in clinical settings will be crucial. This includes establishing guidelines for monitoring and managing adverse events, as well as training healthcare providers in the safe administration of this treatment.